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Abstract:  
Immune Peptide Therapeutics (IPT) LLC, an Indiana-based small business and its research 
partner Indiana University previously identified a novel property of lunasin as a distinct class of 
immune modulating agent that enhances anti-tumor immunity, which may promote disease-free 
survival by limiting tumor progression, and thus prolong lives of cancer patients. Lunasin, a 
synthetic 43-amino acid peptide, was originally isolated from soybeans. Our studies have 
demonstrated that lunasin exerts robust synergistic effects with cytokines on augmenting IFNγ 
and granzyme B expression by Natural Killer (NK) cells, which is associated with increased 
tumoricidal activity of NK cells. In addition, this combination regimen is capable of rescuing IFNγ 
production ex vivo by NK cells from chemotherapy-treated Non-Hodgkin’s Lymphoma (NHL) 
patients who are immunocompromised with acquired immune deficiency. The long-term goal is 
to develop an efficacious immunotherapy which will impact the treatment and improve the 
clinical outcomes for NHL patients. The dose-response study indicates the optimum 
concentration of lunasin is at the range of μM, which would undermine its use in clinical studies. 
To enhance the medicinal value lunasin must be optimized for in vitro and in vivo efficacy. The 
objective is to develop a second generation of lunasin, which will increase its potency to 
improve the performance. In this study we have implemented several strategies to design and 
modify the prototype. The newly developed peptide called IPT.103 has 15 amino acids that are 
in the D-isoform configuration. Activity of IPT.103 has been tested in vitro with EC50 of 0.78 μM 
as compared to 4.54 μM for lunasin. IPT.103 also has in vivo activity on enhancing the serum 
levels of IFNγ production using a mouse model. Taken together, we have developed a peptide 
derivative (IPT.103) that deviates from its parental type lunasin to increase intellectual merit for 
commercialization as well as support clinical application. 
